Effective sequestration of Clostridium difficile protein toxins by calcium aluminosilicate

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7178-7183

  Sturino, Joseph M ^a   Pokusaeva, Karina ^a   Carpenter, Robert ^b,c  

^a TEXAS A AND M UNIVERSITY   (United States)

^b Texas EnteroSorbents   (United States)

^c Salient Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINOSILICATE CALCIUM; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; ALUMINUM SILICATE; BACTERIAL PROTEIN; BACTERIAL TOXIN; ENTEROTOXIN; PROTEIN BINDING; SOLUTION AND SOLUBILITY; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ABSORPTION; ADSORPTION; ANTIBACTERIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME IMMUNOASSAY; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; BIOSYNTHESIS; CHEMISTRY; GENE EXPRESSION; GENETICS; ISOLATION AND PURIFICATION; PATHOGENICITY; PROCEDURES; SOLUTION AND SOLUBILITY; SORPTION DETOXIFICATION;

ALUMINUM SILICATES; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; ENTEROTOXINS; GENE EXPRESSION; IMMUNOENZYME TECHNIQUES; PARTICLE SIZE; PROTEIN BINDING; SOLUTIONS; SORPTION DETOXIFICATION;

EID: 84954565394     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05050-14     Document Type: Article

References (34)

1. Eaton SR, Mazuski JE. 2013. Overview of severe Clostridium difficile infection. Crit Care Clin 29:827-839. http://dx.doi.org/10.1016/j.ccc.2013.06.004.
2. Lessa FC, Gould CV, McDonald LC. 2012. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 55(Suppl 2):S65-S70. http: //dx.doi.org/10.1093/cid/cis319.
3. Gerding DN. 2010. Global epidemiology of Clostridium difficile infection in 2010. Infect Control Hosp Epidemiol 31(Suppl 1):S32-S34. http://dx.doi.org/10.1086/655998.
4. Sunenshine RH, McDonald LC. 2006. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 73:187-197. http://dx.doi.org/10.3949/ccjm.73.2.187.
5. Britton RA, Young VB. 2014. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 146:1547-1553. http://dx.doi.org/10.1053/j.gastro.2014.01.059.
6. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ. 2007. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 45:992-998. http://dx.doi.org/10.1086/521854.
7. Ryan J, Murphy C, Twomey C, Paul Ross R, Rea MC, MacSharry J, Sheil B, Shanahan F. 2010. Asymptomatic carriage of Clostridium difficile in an Irish continuing care institution for the elderly: prevalence and characteristics. Ir J Med Sci 179:245-250. http://dx.doi.org/10.1007/s11845-009-0361-1.
8. Rea MC, O'Sullivan O, Shanahan F, O'Toole PW, Stanton C, Ross RP, Hill C. 2012. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol 50:867-875. http://dx.doi.org/10.1128/JCM.05176-11.
9. Hung YP, Lee JC, Lin HJ, Liu HC, Wu YH, Tsai PJ, Ko WC. 2015. Clinical impact of Clostridium difficile colonization. J Microbiol Immunol Infect 48:241-248. http://dx.doi.org/10.1016/j.jmii.2014.04.011.
10. Pérez-Cobas AE, Artacho A, Ott SJ, Moya A, Gosalbes MJ, Latorre A. 2014. Structural and functional changes in the gut microbiota associated to Clostridium difficile infection. Front Microbiol 5:335. http://dx.doi.org /10.3389/fmicb.2014.00335.
11. Luciano JA, Zuckerbraun BS. 2014. Clostridium difficile infection: prevention, treatment, and surgical management. Surg Clin North Am 94: 1335-1349. http://dx.doi.org/10.1016/j.suc.2014.08.006.
12. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. 1997. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 24:324-333. http://dx.doi.org/10.1093/clinids/24.3.324.
13. Shah D, Dang MD, Hasbun R, Koo HL, Jiang ZD, DuPont HL, Garey KW. 2010. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 8:555-564. http://dx.doi.org/10.1586/eri.10.28.
14. Awad MM, Johanesen PA, Carter GP, Rose E, Lyras D. 2014. Clostridium difficile virulence factors: insights into an anaerobic spore-forming pathogen. Gut Microbes 5:579-593. http://dx.doi.org/10.4161/19490976.2014.969632.
15. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18:247-263. http://dx.doi.org/10.1128/CMR.18.2.247-263.2005.
16. Just I, Gerhard R. 2004. Large clostridial cytotoxins. Rev Physiol Biochem Pharmacol 152:23-47. http://dx.doi.org/10.1007/s10254-004-0033-5.
17. Feltis BA, Wiesner SM, Kim AS, Erlandsen SL, Lyerly DL, Wilkins TD, Wells CL. 2000. Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes. Shock 14:629-634. http://dx.doi.org/10.1097/00024382-200014060-00010.
18. Farrow MA, Chumbler NM, Lapierre LA, Franklin JL, Rutherford SA, Goldenring JR, Lacy DB. 2013. Clostridium difficile toxin B-induced necrosis is mediated by the host epithelial cell NADPH oxidase complex. Proc Natl Acad Sci U S A 110:18674-18679. http://dx.doi.org/10.1073 /pnas.1313658110.
19. Hirota SA, Iablokov V, Tulk SE, Schenck LP, Becker H, Nguyen J, Al Bashir S, Dingle TC, Laing A, Liu J, Li Y, Bolstad J, Mulvey GL, Armstrong GD, MacNaughton WK, Muruve DA, MacDonald JA, Beck PL. 2012. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure. Infect Immun 80:4474-4484. http://dx.doi.org/10.1128/IAI.00933-12.
20. Vohra P, Poxton IR. 2012. Induction of cytokines in a macrophage cell line by proteins of Clostridium difficile. FEMS Immunol Med Microbiol 65:96-104. http://dx.doi.org/10.1111/j.1574-695X.2012.00952.x.
21. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD. 1985. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 47:349-352.
22. Lima AA, Lyerly DM, Wilkins TD, Innes DJ, Guerrant RL. 1988. Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun 56:582-588.
23. Sun X, Savidge T, Feng H. 2010. The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) 2:1848-1880. http://dx.doi.org/10.3390 /toxins2071848.
24. Savidge TC, Pan WH, Newman P, O'Brien M, Anton PM, Pothoulakis C. 2003. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125:413-420. http://dx.doi.org/10.1016/S0016-5085(03)00902-8.
25. Weiss K. 2009. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents 33: 4-7. http://dx.doi.org/10.1016/j.ijantimicag.2008.07.011.
26. Bauer MP, van Dissel JT. 2009. Alternative strategies for Clostridium difficile infection. Int J Antimicrob Agents 33(Suppl 1):S51-S56. http://dx.doi.org/10.1016/S0924-8579(09)70018-4.
27. Electronic Code of Federal Regulations. Title 21. Food and drugs. Chapter I. Food and Drug Administration. Subchapter B. Part 182. Substances generally recognized as safe. Subpart C. Anticaking agents. 21 CFR 182. 2729. http://www.gpo.gov/fdsys/pkg/CFR-2011-title21-vol3/pdf/CFR-2011-title21-vol3-sec182-2729.pdf.
28. Solomon K, Webb J, Ali N, Robins RA, Mahida YR. 2005. Monocytes are highly sensitive to Clostridium difficile toxin A-induced apoptotic and nonapoptotic cell death. Infect Immun 73:1625-1634. http://dx.doi.org /10.1128/IAI.73.3.1625-1634.2005.
29. Fernando SA, Wilson GS. 1992. Studies of the 'hook' effect in the onestep sandwich immunoassay. J Immunol Methods 151:47-66. http://dx.doi.org/10.1016/0022-1759(92)90104-2.
30. Barker RH, Jr, Dagher R, Davidson DM, Marquis JK. 2006. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther 24:1525-1534. http://dx.doi.org/10.1111/j.1365-2036.2006.03157.x.
31. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, Weiss K, Simon S, John JF, Jr, Garber G, Chasan-Taber S, Davidson DM, Tolevamer Study Investigator Group. 2006. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 43:411-420. http://dx.doi.org/10.1086/506349.
32. Hofmann F, Herrmann A, Habermann E, von Eichel-Streiber C. 1995. Sequencing and analysis of the gene encoding the alpha-toxin of Clostridium novyi proves its homology to toxins A and B of Clostridium difficile. Mol Gen Genet 247:670-679. http://dx.doi.org/10.1007/BF00290398.
33. Demarest SJ, Salbato J, Elia M, Zhong J, Morrow T, Holland T, Kline K, Woodnutt G, Kimmel BE, Hansen G. 2005. Structural characterization of the cell wall binding domains of Clostridium difficile toxinsAand B; evidence that Ca2σ plays a role in toxin A cell surface association. J Mol Biol 346:1197-1206. http://dx.doi.org/10.1016/j.jmb.2004.12.059.
34. Mitchell NJ, Kumi J, Aleser M, Elmore SE, Rychlik KA, Zychowski KE, Romoser AA, Phillips TD, Ankrah NA. 2014. Short-term safety and efficacy of calcium montmorillonite clay (UPSN) in children. Am J Trop Med Hyg 91:777-785. http://dx.doi.org/10.4269/ajtmh.14-0093.